[go: up one dir, main page]

PL3010506T3 - Pridopidyna w leczeniu choroby huntingtona - Google Patents

Pridopidyna w leczeniu choroby huntingtona

Info

Publication number
PL3010506T3
PL3010506T3 PL14813621T PL14813621T PL3010506T3 PL 3010506 T3 PL3010506 T3 PL 3010506T3 PL 14813621 T PL14813621 T PL 14813621T PL 14813621 T PL14813621 T PL 14813621T PL 3010506 T3 PL3010506 T3 PL 3010506T3
Authority
PL
Poland
Prior art keywords
pridopidine
disease
treating huntington
huntington
treating
Prior art date
Application number
PL14813621T
Other languages
English (en)
Inventor
Merav Bassan
Eli Eyal
Esther Lukasiewicz Hagai
Anna Kristina Sveinsdotter Teige Wickenberg
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3010506(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3010506T3 publication Critical patent/PL3010506T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14813621T 2013-06-21 2014-06-19 Pridopidyna w leczeniu choroby huntingtona PL3010506T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13
EP14813621.1A EP3010506B1 (en) 2013-06-21 2014-06-19 Pridopidine in treating huntington's disease
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (1)

Publication Number Publication Date
PL3010506T3 true PL3010506T3 (pl) 2021-11-02

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14813621T PL3010506T3 (pl) 2013-06-21 2014-06-19 Pridopidyna w leczeniu choroby huntingtona

Country Status (24)

Country Link
US (1) US10322119B2 (pl)
EP (1) EP3010506B1 (pl)
JP (1) JP2016523862A (pl)
KR (1) KR102316933B1 (pl)
CN (1) CN105592848A (pl)
AU (1) AU2014281414A1 (pl)
BR (1) BR112015029918A2 (pl)
CA (1) CA2913781C (pl)
CL (1) CL2015003690A1 (pl)
DK (1) DK3010506T3 (pl)
EA (1) EA201690069A1 (pl)
ES (1) ES2879631T3 (pl)
HK (1) HK1221646A1 (pl)
HU (1) HUE054783T2 (pl)
IL (1) IL242804B (pl)
MX (1) MX2015017307A (pl)
PE (2) PE20160195A1 (pl)
PH (1) PH12015502691A1 (pl)
PL (1) PL3010506T3 (pl)
SG (1) SG11201509729YA (pl)
TW (1) TW201529069A (pl)
UA (1) UA122999C2 (pl)
UY (1) UY35624A (pl)
WO (1) WO2014205229A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
KR102479759B1 (ko) * 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) * 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
AU2017315783C1 (en) * 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
EP3512517B1 (en) * 2016-09-15 2025-03-19 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of anxiety and depression
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
DK3668509T3 (da) 2017-08-14 2023-02-20 Prilenia Neurotherapeutics Ltd Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
BR112020004045A2 (pt) 2017-08-30 2020-09-01 Prilenia Neurotherapeutics Ltd. formas de dosagem de elevada concentração de pridopidina
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
MX2020002645A (es) 2017-09-08 2021-06-10 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
CA3137633A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
KR101319235B1 (ko) 2004-10-13 2013-10-16 아이백스 인터내셔널 게엠베하 4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
JP6189299B2 (ja) 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
US20140088145A1 (en) 2012-09-27 2014-03-27 Teva Pharmaceutical Industries, Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
AU2013323131A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
KR102479759B1 (ko) 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
AU2017315783C1 (en) * 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
EP3512517B1 (en) 2016-09-15 2025-03-19 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom

Also Published As

Publication number Publication date
JP2016523862A (ja) 2016-08-12
CL2015003690A1 (es) 2016-10-28
KR102316933B1 (ko) 2021-10-26
PE20170302A1 (es) 2017-03-31
CN105592848A (zh) 2016-05-18
CA2913781A1 (en) 2014-12-24
HK1221646A1 (zh) 2017-06-09
BR112015029918A2 (pt) 2017-07-25
US20140378508A1 (en) 2014-12-25
CA2913781C (en) 2022-05-10
SG11201509729YA (en) 2015-12-30
PE20160195A1 (es) 2016-05-14
UY35624A (es) 2015-01-30
MX2015017307A (es) 2016-08-03
IL242804B (en) 2022-02-01
AU2014281414A1 (en) 2016-01-21
ES2879631T3 (es) 2021-11-22
EA201690069A1 (ru) 2016-06-30
US10322119B2 (en) 2019-06-18
WO2014205229A8 (en) 2015-04-09
EP3010506A1 (en) 2016-04-27
EP3010506B1 (en) 2021-05-12
WO2014205229A1 (en) 2014-12-24
UA122999C2 (uk) 2021-02-03
PH12015502691A1 (en) 2016-03-14
HUE054783T2 (hu) 2021-09-28
EP3010506A4 (en) 2017-02-08
KR20160055122A (ko) 2016-05-17
DK3010506T3 (da) 2021-07-12
TW201529069A (zh) 2015-08-01

Similar Documents

Publication Publication Date Title
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
EP3068905A4 (en) Methods and compositions for treating huntington's disease
ZA201406209B (en) Methods and compositions for treating huntington's disease
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
RS65553B1 (sr) Faktor 1 protein za upotrebu u lečenju ili prevenciji bolesti
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
GB201310203D0 (en) Materials and methods relating to Alzheimer's disease
PT2980096T (pt) Métodos de preparação de 2,3,5 tri-hidroxi-androst-6-ona e utilização do mesmo
HK1223827A1 (zh) 用於治療眼疾病的 調節劑
GB201214450D0 (en) Huntington's disease
AU353890S (en) Men's clothing
ZA201407032B (en) Preventing or treating periodontal disease
GB201309694D0 (en) Artist's implement
GB201310607D0 (en) B'jamas
GB201310101D0 (en) Treatment of freidreich's ataxia
AU350798S (en) Alu' sling sunlounger
GB201322568D0 (en) Taggstar 1
BR302013005287S1 (pt) Configuração introduzida em calçado feminino
GB201309270D0 (en) Line-out Rugby aid 'Get Up's'
GB201301407D0 (en) 17 Deemed-Ties Blackjack
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270
GB201311499D0 (en) Concept 7